The University of Arizona
Map Home
Loading...
Adjust height of sidebar
KMap

Grant

Randomized Phase 2 Study of DKN-01 Plus FOLFIRI/FOLFOX and Bevacizumab Versus FOLFIRI/FOLFOX and Bevacizumab as Second-line Treatment of Advanced Colorectal Cancer (DeFianCe)

Sponsored by Leap Therapeutics, Inc.

Active
$568.2K Funding
7 People
External

Related Topics

People